The Disruptive Anti-IgE Molecule KIH_E07_79 Rapidly Desensitizes Allergic Effector Cells and Suppresses IgE Production in B-cells

Due to its key roles in the development and manifestation of allergic reactions, immunoglobulin E (IgE) has become an interesting molecular target. The monoclonal anti-IgE antibody omalizumab, which primarily inhibits IgE binding to its high-affinity receptor, Fc εRI⍺, on allergic effector cells has shown remarkable therapeutic success in various allergic indications. Recently, we have described an alternative anti-IgE molecule, termed KIH_E07_79, which in addition to the neutralization of free IgE rapidly disrupts pre-formed IgE-FcεRI complexes and ther eby stops pre-initiated systemic anaphylaxis in mice.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research